b5b1ff3206f46b137026b38b6f199073cf3c1977 kuhn Fri Jan 24 17:02:06 2020 -0800 made curated and submitted more obvious in description. added mention of use of teh word Coverage. Per Ana Benet. Refs #24817 diff --git src/hg/makeDb/trackDb/human/iscaComposite.html src/hg/makeDb/trackDb/human/iscaComposite.html index 9db22f9..fbdce7a 100644 --- src/hg/makeDb/trackDb/human/iscaComposite.html +++ src/hg/makeDb/trackDb/human/iscaComposite.html @@ -30,70 +30,71 @@ <P> The <a href="https://www.clinicalgenome.org/" target="_blank">Clinical Genome Resource</a> (ClinGen) is a National Institutes of Health (NIH)-funded program dedicated to building a genomic knowledge base to improve patient care. This will be accomplished by harnessing the data from both research efforts and clinical genetic testing, and using it to propel expert and machine-driven curation activities. By facilitating collaboration within the genomics community, we will all better understand the relationship between genomic variation and human health. ClinGen will work closely with the National Center for Biotechnology Information (NCBI) of the National Library of Medicine (NLM), which will distribute this information through its ClinVar database. </P> <p> -The ClinGen dataset displays clinical microarray data submitted to dbGaP/dbVar at NCBI +The ClinGen dataset displays clinical microarray data <b>submitted</b> to dbGaP/dbVar at NCBI by ClinGen member laboratories (dbVar study <a href="https://www.ncbi.nlm.nih.gov/dbvar/studies/nstd37/" target="_blank">nstd37</a>), as well as clinical data reported in Kaminsky <i>et al.</i>, 2011 (dbVar study <a href="https://www.ncbi.nlm.nih.gov/dbvar/studies/nstd101" target="_blank">ntsd101</a>) (see reference below). This track shows copy number variants (CNVs) found in patients referred for genetic testing for indications such as intellectual disability, developmental delay, -autism and congenital anomalies. Additionally, the ClinGen "Curated Pathogenic" and -"Curated Benign" tracks represent genes/genomic regions reviewed for dosage sensitivity +autism and congenital anomalies. Additionally, the ClinGen "<b>Curated</b> Pathogenic" and +"<b>Curated</b> Benign" tracks represent genes/genomic regions reviewed for dosage sensitivity in an evidence-based manner by the ClinGen Structural Variation Working Group (dbVar study <a href="https://www.ncbi.nlm.nih.gov/dbvar/studies/nstd45/" target="_blank">nstd45</a>). </p> <P>The CNVs in this study have been reviewed for their clinical significance by the submitting ClinGen laboratory. Some of the deletions and duplications in the track have been reported as causative for a phenotype by the submitting clinical laboratory; this information was based on current knowledge at the time of submission. However, it should be noted that phenotype information is often vague and imprecise and should be used with caution. While all samples were submitted because of a phenotype in a patient, only 15% of patients had variants determined to be causal, and most patients will have additional variants that are not causal. </P> <P>CNVs are separated into subtracks and are labeled as: <ul> <li>Pathogenic</li> <li>Uncertain: Likely Pathogenic</li> <li>Uncertain</li> <li>Uncertain: Likely Benign</li> <li>Benign</li> </ul> The user should be aware that some of the data were submitted using a 3-class system, with the two "Likely" categories omitted. </P> <P> Two subtracks, "Path Gain" and "Path Loss", are aggregate tracks showing graphically the accumulated level of gains and losses in the Pathogenic subtrack across the genome. Similarly, "Benign Gain" and "Benign Loss" show the accumulated level of gains and losses in the -Benign subtrack. +Benign subtrack. These tracks are collectively called "<b>Coverage</b>" +tracks. </P> <P> Many samples have multiple variants, not all of which are causative of the phenotype. The CNVs in these samples have been decoupled, so it is not possible to connect multiple imbalances as coming from a single patient. It is therefore not possible to identify individuals via their genotype. </P> <H2>Methods and Color Convention</H2> <P> The samples were analyzed by arrays from patients referred for cytogenetic testing due to clinical phenotypes. Samples were analyzed with a probe spacing of 20-75 kb. The minimum CNV breakpoints are shown; if available, the maximum CNV breakpoints are provided in the details page, but are not shown